Peer Review History

Original SubmissionMay 25, 2022
Decision Letter - Tamas Zakar, Editor

PONE-D-22-15156MicroRNA analysis in maternal blood of pregnancies with preterm premature rupture of membranes reveals a distinct expression profilePLOS ONE

Dear Dr. Spiliopoulos,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we believe that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please address the Reviewer's concerns point-by-point in your response. In addition, please include the requested clinical information in the revised version, acknowledge the limitations (e.g., cause or effect of PPROM, need for a validation cohort) and adjust the conclusions accordingly.

Please submit your revised manuscript by Sep 01 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Tamas Zakar

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The results from this study have shown that there is a differential expression of specific miRNAs between PPROM and healthy controls in a small number of samples. The number of samples is very limited and due to the PPROM samples being collected at the time of hospital admission, it is not possible to determine whether these miRNAs are predictive or diagnostic of PPROM.

As it is not possible to distinguish the differential expression of miRNAs that could potentially lead to PPROM and those that are caused by PPROM, the bioinformatics work identifying potential targets of these miRNA markers would not be meaningful.

The study needs to include a validation cohort to further examine the differential expression of the identified miRNAs.

In addition, there is lack of information about how the samples were collected and processed. This is important to include as various factors such as phlebotomy variables, storage conditions/times, blood cell content, presence of clots/haemolysis, and processing can affect miRNA expression in serum.

There is important information on patient characteristics that is missing. Most of the patients were multiparous, but no information is given whether they previously had a term or preterm deliveries. It is also helpful to describe whether the cohort of patients went into spontaneous labour with PPROM or whether they were induced and some further information to explain why there is a 50% caesarean section rate for these patients.

Reviewer #2: This study is well-written and tried to find answer for PPROM pathogenesis. The material method is well defined and the results are presented accurately.It has originality and have interest inn this field. and It can be published.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Response to Reviewers:

Reviewer #1:

“The results from this study have shown that there is a differential expression of specific miRNAs between PPROM and healthy controls in a small number of samples. The number of samples is very limited and due to the PPROM samples being collected at the time of hospital admission, it is not possible to determine whether these miRNAs are predictive or diagnostic of PPROM.

As it is not possible to distinguish the differential expression of miRNAs that could potentially lead to PPROM and those that are caused by PPROM, the bioinformatics work identifying potential targets of these miRNA markers would not be meaningful.”

We agree with the above reviewer comment regarding our study design not being able to differentiate between predictive and diagnostic markers for PPROM. This limitation is stated in both the “Clinical implications” as well as “Limitations” sections of the manuscript.

However, as noted by the title and conclusion of our study, our primary goal was to shed some light in the pathophysiology of PPROM rather than attempt to identify predictive biomarkers. Hence, we believe there is value in identifying targets for the differentially expressed miRNAs.

Manuscript text and conclusions have been modified accordingly.

“The study needs to include a validation cohort to further examine the differential expression of the identified miRNAs.”

We acknowledge the lack of a validation cohort in our study. Even though the criteria set for FDR in our microarray study were very stringent there is still a possibility that qRT-PCR might identify different expression levels for the differentially expressed miRNAs.

Manuscript was edited to acknowledge the above.

“There is important information on patient characteristics that is missing. Most of the patients were multiparous, but no information is given whether they previously had a term or preterm deliveries. It is also helpful to describe whether the cohort of patients went into spontaneous labour with PPROM or whether they were induced and some further information to explain why there is a 50% caesarean section rate for these patients.”

In the PPROM group, 4 patients (40%) had a history of preterm delivery compared with no patients in the control group having such history. Three patients in the PPROM group (30%) went into spontaneous labor while two (20%) were induced. Indications for c-section (50%) in the PPROM group included placenta previa (10%), malpresentation (30%) and chorioamnionitis with non-reassuring fetal heart rate pattern (10%).

The above information was added to the manuscript.

“In addition, there is lack of information about how the samples were collected and processed. This is important to include as various factors such as phlebotomy variables, storage conditions/times, blood cell content, presence of clots/haemolysis, and processing can affect miRNA expression in serum.”

Blood samples were drawn from our patients on admission to the hospital, serum was isolated by centrifugation (1600g, 15 minutes at 4°C) from whole blood in less than 4 hours after collection and frozen immediately at -80 ̊C. Samples were checked for the presence of small clots and hemolysis. Specimens were maintained frozen for the duration of the study period and were shipped from Washington Hospital Center (Washington, DC, USA) directly to Georgetown University Department of Physiology (Washington, DC, USA) on dry ice where they remained blinded as to clinical outcome through testing, identified only by a unique identification number.

We included the above in the manuscript.

“Please address the Reviewer's concerns point-by-point in your response. In addition, please include the requested clinical information in the revised version, acknowledge the limitations (e.g., cause or effect of PPROM, need for a validation cohort) and adjust the conclusions accordingly.”

Above comments from the Academic Editor were addressed in the manuscript as well.

Attachments
Attachment
Submitted filename: Response to Reviewers - miRNA.docx
Decision Letter - Tamas Zakar, Editor

MicroRNA analysis in maternal blood of pregnancies with preterm premature rupture of membranes reveals a distinct expression profile

PONE-D-22-15156R1

Dear Dr. Spiliopoulos,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Tamas Zakar

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Tamas Zakar, Editor

PONE-D-22-15156R1

MicroRNA analysis in maternal blood of pregnancies with preterm premature rupture of membranes reveals a distinct expression profile

Dear Dr. Spiliopoulos:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Tamas Zakar

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .